About
Contact & Profiles
A5048382924
Research Areas
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Breast Lesions and Carcinomas
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Moscow Clinical Scientific Center
2020-2025
Background . Treatment results for the patients with stage II–III triple negative breast cancer (TN BC) have to be improved. Not only new treatment regimens, but predictive and prognostic factors should developed. Materials methods We included 98 TN BC in our study. studied efficacy safety of PlaTax regimen (cisplatin 75 mg / m 2 day 1 + paclitaxel 80 days 1, 8, 15, course every 4 weeks) this cohort patients. assessed pathologic response, survival factors, which were relevant predicting...
10.17650/1994-4098-2020-16-2-25-37
article
EN
cc-by
Tumors of female reproductive system
2020-11-17
Coming Soon ...